| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Bacterial Agents | 26 | 2020 | 402 | 3.620 |
Why?
|
| Daptomycin | 9 | 2013 | 13 | 1.780 |
Why?
|
| Staphylococcal Infections | 6 | 2018 | 176 | 1.370 |
Why?
|
| Prosthesis-Related Infections | 7 | 2020 | 214 | 1.220 |
Why?
|
| Anti-Infective Agents | 11 | 2005 | 63 | 1.100 |
Why?
|
| Cross Infection | 5 | 2023 | 298 | 1.100 |
Why?
|
| Bacterial Infections | 6 | 2011 | 69 | 0.970 |
Why?
|
| Gram-Positive Bacterial Infections | 5 | 2013 | 57 | 0.960 |
Why?
|
| Fluoroquinolones | 8 | 2011 | 26 | 0.940 |
Why?
|
| Clostridium Infections | 1 | 2023 | 18 | 0.930 |
Why?
|
| Communicable Diseases | 1 | 2023 | 24 | 0.930 |
Why?
|
| Staphylococcus aureus | 7 | 2018 | 85 | 0.840 |
Why?
|
| Infection Control | 3 | 2018 | 169 | 0.800 |
Why?
|
| Catheterization, Central Venous | 2 | 2011 | 39 | 0.710 |
Why?
|
| Skin Diseases, Bacterial | 3 | 2018 | 5 | 0.670 |
Why?
|
| Surgical Wound Infection | 2 | 2017 | 97 | 0.660 |
Why?
|
| Sepsis | 3 | 2011 | 144 | 0.660 |
Why?
|
| Bacteria | 4 | 2011 | 77 | 0.650 |
Why?
|
| Soft Tissue Infections | 3 | 2018 | 28 | 0.640 |
Why?
|
| Bacteremia | 2 | 2010 | 115 | 0.610 |
Why?
|
| Enterococcus | 4 | 2013 | 56 | 0.590 |
Why?
|
| Humans | 54 | 2023 | 29337 | 0.580 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2016 | 124 | 0.560 |
Why?
|
| Arthroplasty, Replacement | 1 | 2017 | 147 | 0.530 |
Why?
|
| Microbial Sensitivity Tests | 13 | 2018 | 111 | 0.490 |
Why?
|
| Endocarditis, Bacterial | 2 | 2006 | 10 | 0.470 |
Why?
|
| Oxazolidinones | 2 | 2010 | 6 | 0.460 |
Why?
|
| Acetamides | 2 | 2010 | 7 | 0.450 |
Why?
|
| Vancomycin Resistance | 2 | 2010 | 28 | 0.450 |
Why?
|
| Drug Resistance, Bacterial | 3 | 2011 | 53 | 0.430 |
Why?
|
| Chlamydia trachomatis | 5 | 1994 | 18 | 0.420 |
Why?
|
| Quinolones | 5 | 1991 | 21 | 0.390 |
Why?
|
| Methicillin Resistance | 2 | 2008 | 31 | 0.390 |
Why?
|
| Retrospective Studies | 11 | 2023 | 3273 | 0.350 |
Why?
|
| Antibiotic Prophylaxis | 3 | 2016 | 36 | 0.350 |
Why?
|
| Catheters, Indwelling | 1 | 2008 | 25 | 0.330 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2019 | 16 | 0.330 |
Why?
|
| Hospitals, University | 1 | 2008 | 39 | 0.320 |
Why?
|
| Attitude of Health Personnel | 1 | 2009 | 148 | 0.320 |
Why?
|
| Benchmarking | 1 | 2008 | 41 | 0.320 |
Why?
|
| Pneumonia, Bacterial | 2 | 2005 | 9 | 0.310 |
Why?
|
| Quality of Health Care | 2 | 2011 | 138 | 0.310 |
Why?
|
| Diarrhea | 4 | 1999 | 48 | 0.310 |
Why?
|
| Cefazolin | 2 | 2018 | 5 | 0.300 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2009 | 194 | 0.300 |
Why?
|
| Gram-Negative Bacterial Infections | 2 | 2007 | 24 | 0.290 |
Why?
|
| Erythromycin | 2 | 1996 | 11 | 0.270 |
Why?
|
| Bone Diseases | 1 | 2005 | 24 | 0.270 |
Why?
|
| United States | 6 | 2017 | 2333 | 0.270 |
Why?
|
| Gram-Negative Aerobic Bacteria | 1 | 2005 | 5 | 0.270 |
Why?
|
| Microbiological Techniques | 2 | 2016 | 9 | 0.270 |
Why?
|
| Critical Care | 1 | 2008 | 234 | 0.270 |
Why?
|
| Arthroplasty, Replacement, Knee | 3 | 2020 | 696 | 0.260 |
Why?
|
| Arthroplasty, Replacement, Hip | 3 | 2020 | 863 | 0.260 |
Why?
|
| Ambulatory Care | 1 | 2005 | 75 | 0.260 |
Why?
|
| Infection Control Practitioners | 1 | 2004 | 2 | 0.250 |
Why?
|
| Joint Diseases | 1 | 2005 | 110 | 0.250 |
Why?
|
| Equipment Contamination | 1 | 2004 | 24 | 0.250 |
Why?
|
| Ambulatory Care Facilities | 1 | 2004 | 37 | 0.240 |
Why?
|
| Carrier State | 2 | 2018 | 53 | 0.230 |
Why?
|
| Knee Prosthesis | 2 | 2020 | 248 | 0.230 |
Why?
|
| Hospitals | 1 | 2023 | 157 | 0.220 |
Why?
|
| Treatment Outcome | 10 | 2015 | 3478 | 0.210 |
Why?
|
| Disease Management | 2 | 2019 | 114 | 0.200 |
Why?
|
| Hip Prosthesis | 3 | 2020 | 605 | 0.190 |
Why?
|
| Cephalosporins | 3 | 1997 | 17 | 0.190 |
Why?
|
| Adult | 13 | 2018 | 8601 | 0.190 |
Why?
|
| Orthopedic Fixation Devices | 1 | 1999 | 24 | 0.180 |
Why?
|
| Heart Valve Prosthesis | 1 | 1999 | 22 | 0.180 |
Why?
|
| Male | 17 | 2020 | 15621 | 0.180 |
Why?
|
| Discitis | 1 | 2019 | 4 | 0.180 |
Why?
|
| Surgical Procedures, Operative | 1 | 2019 | 31 | 0.180 |
Why?
|
| Genes, Bacterial | 1 | 2018 | 6 | 0.170 |
Why?
|
| Carbapenem-Resistant Enterobacteriaceae | 1 | 2018 | 13 | 0.170 |
Why?
|
| Linezolid | 2 | 2010 | 6 | 0.160 |
Why?
|
| Middle Aged | 12 | 2020 | 9823 | 0.160 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2018 | 38 | 0.160 |
Why?
|
| Fasciitis, Necrotizing | 1 | 2018 | 4 | 0.160 |
Why?
|
| Ciprofloxacin | 4 | 1993 | 29 | 0.160 |
Why?
|
| Reoperation | 2 | 2020 | 932 | 0.150 |
Why?
|
| Aged | 10 | 2020 | 9448 | 0.150 |
Why?
|
| Meningitis, Bacterial | 1 | 1996 | 8 | 0.150 |
Why?
|
| Mass Screening | 1 | 2018 | 177 | 0.150 |
Why?
|
| Legionella pneumophila | 1 | 1996 | 1 | 0.150 |
Why?
|
| Clarithromycin | 1 | 1996 | 5 | 0.150 |
Why?
|
| Azithromycin | 1 | 1996 | 4 | 0.140 |
Why?
|
| Campylobacter Infections | 3 | 1993 | 12 | 0.140 |
Why?
|
| Prosthesis Failure | 1 | 2020 | 556 | 0.140 |
Why?
|
| Female | 13 | 2020 | 16197 | 0.140 |
Why?
|
| Oxacillin | 1 | 2015 | 2 | 0.140 |
Why?
|
| Methicillin | 1 | 2015 | 6 | 0.140 |
Why?
|
| Chicago | 4 | 2018 | 865 | 0.140 |
Why?
|
| Arthroplasty | 1 | 2016 | 136 | 0.140 |
Why?
|
| Drug Hypersensitivity | 1 | 1995 | 17 | 0.130 |
Why?
|
| Sexually Transmitted Diseases, Bacterial | 2 | 1991 | 3 | 0.130 |
Why?
|
| Aged, 80 and over | 6 | 2018 | 4851 | 0.130 |
Why?
|
| Ceftizoxime | 1 | 1994 | 2 | 0.130 |
Why?
|
| Neisseria gonorrhoeae | 2 | 1991 | 7 | 0.120 |
Why?
|
| Cyclic N-Oxides | 1 | 1993 | 5 | 0.120 |
Why?
|
| Campylobacter | 1 | 1993 | 8 | 0.120 |
Why?
|
| Endocarditis | 1 | 2013 | 8 | 0.120 |
Why?
|
| Quinoxalines | 1 | 1993 | 11 | 0.120 |
Why?
|
| Enterococcus faecalis | 1 | 2013 | 7 | 0.120 |
Why?
|
| Enterococcus faecium | 1 | 2013 | 15 | 0.120 |
Why?
|
| Drug Resistance, Microbial | 4 | 1996 | 96 | 0.110 |
Why?
|
| Drainage | 1 | 2013 | 50 | 0.110 |
Why?
|
| Campylobacter jejuni | 1 | 1992 | 4 | 0.110 |
Why?
|
| Uterine Cervicitis | 1 | 1991 | 2 | 0.110 |
Why?
|
| Urethritis | 1 | 1991 | 2 | 0.110 |
Why?
|
| Cohort Studies | 3 | 2015 | 1939 | 0.110 |
Why?
|
| Aza Compounds | 1 | 2011 | 1 | 0.110 |
Why?
|
| Administration, Ophthalmic | 1 | 2011 | 1 | 0.110 |
Why?
|
| Azepines | 1 | 2011 | 6 | 0.100 |
Why?
|
| Quinolines | 1 | 2011 | 16 | 0.100 |
Why?
|
| Risk Factors | 2 | 2011 | 2443 | 0.100 |
Why?
|
| 4-Quinolones | 4 | 1995 | 6 | 0.100 |
Why?
|
| Serratia marcescens | 1 | 2010 | 11 | 0.100 |
Why?
|
| Serratia Infections | 1 | 2010 | 10 | 0.100 |
Why?
|
| Naphthyridines | 1 | 1990 | 2 | 0.100 |
Why?
|
| Risk Reduction Behavior | 1 | 2011 | 55 | 0.100 |
Why?
|
| Cost-Benefit Analysis | 1 | 2011 | 144 | 0.090 |
Why?
|
| Health Care Costs | 1 | 2011 | 70 | 0.090 |
Why?
|
| Data Interpretation, Statistical | 1 | 2010 | 96 | 0.090 |
Why?
|
| Disease Outbreaks | 1 | 2010 | 88 | 0.090 |
Why?
|
| Doxycycline | 4 | 2006 | 22 | 0.090 |
Why?
|
| Illinois | 1 | 2011 | 241 | 0.090 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 324 | 0.090 |
Why?
|
| Tetracyclines | 1 | 1989 | 3 | 0.090 |
Why?
|
| Intensive Care Units | 2 | 2018 | 301 | 0.090 |
Why?
|
| Models, Biological | 1 | 2011 | 343 | 0.090 |
Why?
|
| Rifampin | 1 | 1989 | 7 | 0.090 |
Why?
|
| Minocycline | 1 | 1989 | 8 | 0.090 |
Why?
|
| Shock, Septic | 1 | 1989 | 62 | 0.080 |
Why?
|
| Time Factors | 4 | 2020 | 1616 | 0.080 |
Why?
|
| Neurocognitive Disorders | 1 | 1988 | 19 | 0.080 |
Why?
|
| Algorithms | 1 | 2010 | 400 | 0.080 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1988 | 90 | 0.080 |
Why?
|
| Guideline Adherence | 1 | 2008 | 67 | 0.080 |
Why?
|
| Quality Indicators, Health Care | 1 | 2008 | 39 | 0.080 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2007 | 16 | 0.080 |
Why?
|
| Vancomycin | 1 | 2008 | 57 | 0.080 |
Why?
|
| Skin Diseases, Infectious | 1 | 2007 | 9 | 0.080 |
Why?
|
| Prognosis | 1 | 2010 | 840 | 0.080 |
Why?
|
| Q Fever | 1 | 2006 | 4 | 0.070 |
Why?
|
| Travel | 1 | 2006 | 13 | 0.070 |
Why?
|
| Community-Acquired Infections | 2 | 2005 | 78 | 0.070 |
Why?
|
| Registries | 1 | 2007 | 188 | 0.070 |
Why?
|
| Tobramycin | 1 | 2005 | 9 | 0.070 |
Why?
|
| Calcium Sulfate | 1 | 2005 | 19 | 0.070 |
Why?
|
| Bone Substitutes | 1 | 2005 | 25 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2011 | 437 | 0.070 |
Why?
|
| Feces | 1 | 2005 | 98 | 0.060 |
Why?
|
| Humerus | 1 | 2005 | 98 | 0.060 |
Why?
|
| Animals | 2 | 2011 | 4552 | 0.060 |
Why?
|
| Joint Commission on Accreditation of Healthcare Organizations | 1 | 2004 | 5 | 0.060 |
Why?
|
| Bone Transplantation | 1 | 2005 | 224 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 1 | 2005 | 333 | 0.060 |
Why?
|
| Administration, Oral | 2 | 2020 | 140 | 0.060 |
Why?
|
| Drug Synergism | 2 | 1994 | 63 | 0.050 |
Why?
|
| Gram-Negative Bacteria | 2 | 2007 | 37 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2006 | 389 | 0.050 |
Why?
|
| Ofloxacin | 2 | 1997 | 5 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2005 | 1830 | 0.050 |
Why?
|
| Parasitic Diseases | 1 | 1999 | 4 | 0.040 |
Why?
|
| Virus Diseases | 1 | 1999 | 17 | 0.040 |
Why?
|
| Bacterial Load | 1 | 2018 | 13 | 0.040 |
Why?
|
| Gas Gangrene | 1 | 2018 | 1 | 0.040 |
Why?
|
| Rectum | 1 | 2018 | 61 | 0.040 |
Why?
|
| Leukocidins | 1 | 2018 | 2 | 0.040 |
Why?
|
| Dermatomycoses | 1 | 2018 | 3 | 0.040 |
Why?
|
| Exotoxins | 1 | 2018 | 14 | 0.040 |
Why?
|
| Pyomyositis | 1 | 2018 | 5 | 0.040 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2018 | 12 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2018 | 65 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2018 | 29 | 0.040 |
Why?
|
| Immunoglobulins | 1 | 2018 | 28 | 0.040 |
Why?
|
| Bacterial Toxins | 1 | 2018 | 21 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2020 | 495 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2018 | 45 | 0.040 |
Why?
|
| Prodrugs | 1 | 1997 | 4 | 0.040 |
Why?
|
| Ceftriaxone | 1 | 1997 | 5 | 0.040 |
Why?
|
| Macrolides | 2 | 1994 | 6 | 0.040 |
Why?
|
| Cefuroxime | 1 | 1997 | 2 | 0.040 |
Why?
|
| Levofloxacin | 1 | 1997 | 5 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 142 | 0.040 |
Why?
|
| Prevalence | 1 | 2018 | 487 | 0.040 |
Why?
|
| Legionnaires' Disease | 1 | 1996 | 1 | 0.040 |
Why?
|
| Emergencies | 1 | 1996 | 39 | 0.040 |
Why?
|
| Bacteriological Techniques | 1 | 1996 | 20 | 0.040 |
Why?
|
| Acute Disease | 1 | 1996 | 226 | 0.030 |
Why?
|
| Listeriosis | 1 | 1995 | 5 | 0.030 |
Why?
|
| Skin Tests | 1 | 1995 | 14 | 0.030 |
Why?
|
| Adolescent | 2 | 2018 | 2279 | 0.030 |
Why?
|
| Staphylococcus | 1 | 1995 | 10 | 0.030 |
Why?
|
| Drug Utilization | 1 | 1995 | 27 | 0.030 |
Why?
|
| Arthritis, Infectious | 1 | 1995 | 59 | 0.030 |
Why?
|
| Kinetics | 1 | 1994 | 225 | 0.030 |
Why?
|
| Campylobacter coli | 1 | 1993 | 2 | 0.030 |
Why?
|
| Metronidazole | 1 | 1993 | 8 | 0.030 |
Why?
|
| Borrelia burgdorferi Group | 1 | 1993 | 6 | 0.030 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 1993 | 16 | 0.030 |
Why?
|
| Contraindications | 1 | 2013 | 41 | 0.030 |
Why?
|
| Blood | 1 | 2013 | 25 | 0.030 |
Why?
|
| Creatine Kinase | 1 | 2013 | 33 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 223 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2013 | 298 | 0.030 |
Why?
|
| Serial Passage | 1 | 1992 | 2 | 0.030 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 1992 | 2 | 0.030 |
Why?
|
| Osteoarthritis, Hip | 1 | 2013 | 94 | 0.030 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 1992 | 9 | 0.030 |
Why?
|
| Ureaplasma urealyticum | 1 | 1991 | 1 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2013 | 1811 | 0.030 |
Why?
|
| Mycoplasma | 1 | 1991 | 4 | 0.030 |
Why?
|
| Treponema pallidum | 1 | 1991 | 4 | 0.030 |
Why?
|
| Young Adult | 1 | 2018 | 1932 | 0.030 |
Why?
|
| Gonorrhea | 1 | 1991 | 8 | 0.030 |
Why?
|
| Serratia | 1 | 2010 | 7 | 0.020 |
Why?
|
| Syringes | 1 | 2010 | 11 | 0.020 |
Why?
|
| Blood Sedimentation | 1 | 2010 | 64 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2010 | 50 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2010 | 130 | 0.020 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 1990 | 7 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2010 | 125 | 0.020 |
Why?
|
| Mutation | 1 | 1992 | 383 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2010 | 90 | 0.020 |
Why?
|
| Norfloxacin | 1 | 1989 | 2 | 0.020 |
Why?
|
| Hip Joint | 1 | 2013 | 367 | 0.020 |
Why?
|
| Urinary Tract Infections | 1 | 1989 | 32 | 0.020 |
Why?
|
| Osteoarthritis, Knee | 1 | 2013 | 381 | 0.020 |
Why?
|
| Pneumonia | 1 | 1989 | 67 | 0.020 |
Why?
|
| Knee Joint | 1 | 2013 | 797 | 0.020 |
Why?
|
| Coxiella burnetii | 1 | 2006 | 3 | 0.020 |
Why?
|
| Antigens, Bacterial | 1 | 2006 | 7 | 0.020 |
Why?
|
| Australia | 1 | 2006 | 44 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 1113 | 0.020 |
Why?
|
| Drug Implants | 1 | 2005 | 11 | 0.020 |
Why?
|
| Osteomyelitis | 1 | 2005 | 22 | 0.020 |
Why?
|
| Dogs | 1 | 2005 | 253 | 0.020 |
Why?
|
| Radiography | 1 | 2005 | 678 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1997 | 56 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 1997 | 241 | 0.010 |
Why?
|
| Kidney Transplantation | 1 | 1995 | 125 | 0.010 |
Why?
|
| Dysentery, Bacillary | 1 | 1990 | 2 | 0.010 |
Why?
|
| Campylobacter fetus | 1 | 1990 | 4 | 0.010 |
Why?
|
| Salmonella Infections | 1 | 1990 | 3 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 1990 | 503 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1990 | 340 | 0.010 |
Why?
|